Merck KGaA ADR
USUSDMerck KGaA ADR (VI:MRK) — Biotechnology: Pharmaceutical Preparations. Börside arv, kus ettevõtte aktsiatega kaubeldakse: 6. Sellel lehel — hind ja graafik, dividendid, suurimad aktsionärid ja aktsiate arvu ajalugu.
- Merck KGaA — MRK · XETRA DE Registreerimisnumber teadmata
Ettevõtte Kohta
- Veebileht
- merck.com
- Investorite Suhted
- merck.com/investor-relations/
- Sektor
- Health Care · Biotechnology: Pharmaceutical Preparations
- Peakontor
- RAHWAY, Germany
- Tegevjuht
- Kai Beckmann
- Töötajad
- 62 136
- Börsil Alates
- 22.05.2017 (VI:MRK)
- Ringluses Olevad Aktsiad
- 2.47 mld seisuga 2026-07-31
- Vabalt Kaubeldavad Aktsiad
- 644.35 mln
- Turukapitalisatsioon
- 67.93 mld USD
- Siseringi Isikud
- 0%
- Institutsionaalsed Investorid
- 0.02%
- Tegevusala (SIC)
- Pharmaceutical Preparations
- Õiguslik Vorm
- XSNP
- ISIN
- US58933Y1055
- LEI
- 4YV9Y5M8S0BRK1RP0397
- P/E
- 116
- Väljamaksesuhe
- 262%
- FCF
- 16.1 mld USD
- Väljamakse / FCF
- 52%
- Võlg
- 51.1 mld USD2.8 a FCF
- Dividendistaaž
- 56+ a
- Kasum, FCF ja dividendid makstud — 12 kuu jooksul kuni 30.06.2026 (ettevõtte viimane raport).
- NAV
Kirjeldus
Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. The Life Science segment offers products, solutions, and services to academic, research and diagnostic labs, biotech, and pharmaceutical companies, as well as the industrial sector; reagents, consumables, devices, instruments, software, and services for research, production, and testing to lab water instruments, microbiology and biomonitoring products, test assays, analytical reagents, and flow cytometry kits and instruments. This segment also provides traditional and novel therapies, such as ration devices, chromatography resins, single-use systems, process chemicals, and excipients for bioprocessing; contract development, manufacturing and testing services, which supports customers from preclinical phases to commercialization. The Healthcare segment discovers, develops, manufactures, and markets prescription drugs and biopharmaceuticals to the therapeutic areas of oncology, rare diseases, neurology and immunology, fertility, cardiovascular, and metabolic and endocrinological disorders. The Electronics segment offers advanced dielectric and metallic materials; photoresist, anti-reflective coating, and material lithography products; clean and selective etch chemistries; materials for chemical-mechanical planarization; high-purity gases for semiconductor manufacturing; and develops and installs delivery equipment for handling of specialty chemicals and gases for semiconductor manufacturing; develops modulating, creating, engineering, and guiding light; and material solutions in liquid crystals, OLED materials, and photoresists. It has in-licensing agreement with Abbisko Therapeutics Co. Ltd., China on drug candidates for the treatment of tenosynovial giant cell tumor; and strategic partnership with Versant Ventures to advance treatments for rare genetic cardiomyopathies. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KG.
Börsid ja Tikkerid
| Börs | Tikker | Valuuta | Hind | Tüüp |
|---|---|---|---|---|
| US USA Stocks | MRK lisanoteering | USD | 145.19 -1.48% | tavalised aktsiad |
| LSE London Stock Exchange | 0QAH IOB | USD | 148.65 -0.12% | tavalised aktsiad |
| MI Borsa Italiana (Milan) | 1MRKX põhinoteering | EUR | 130.34 -3.28% | tavalised aktsiad |
| MX Mexican Stock Exchange | MRK lisanoteering | MXN | 2 688.51 -0.72% | tavalised aktsiad |
| VI Vienna Stock Exchange | MRK lisanoteering | EUR | 124.84 -2.79% | tavalised aktsiad |
| XETRA Xetra | 6MK lisanoteering | EUR | 129.78 +0.09% | tavalised aktsiad |
Dividendid
Merck KGaA ADR (MRK) maksab dividende kvartalis. Aastas (12 kuud kuni viimase teatatud maksega): 3.0342 EUR aktsia kohta (maksed: 4). See on umbes 2.43% praegusest aktsiahinnast. Makseajaloo põhjal oodatakse järgmist ex-dividendi kuupäeva umbes 15.12.2026. Katkematu dividendiajalugu: 56 aastat.
| Ex-Kuupäev | Väljamakse | Summa | % | Tüüp | Tikker |
|---|---|---|---|---|---|
| 2026-09-15 | — | 0.7585 EUR | 0.6/2.4 % | kord kvartalis | VI:MRK |
| 2026-06-15 | — | 0.7585 EUR | 0.7/2.9 % | kord kvartalis | VI:MRK |
| 2026-03-16 | — | 0.7585 EUR | 0.8/3.0 % | kord kvartalis | VI:MRK |
| 2025-12-15 | — | 0.7585 EUR | 0.9/3.5 % | kord kvartalis | VI:MRK |
| 2025-09-15 | — | 0.7228 EUR | 1.0/4.0 % | kord kvartalis | VI:MRK |
| 2025-06-16 | — | 0.7228 EUR | 1.0/4.1 % | kord kvartalis | VI:MRK |
| 2025-03-17 | — | 0.7228 EUR | 0.8/3.2 % | kord kvartalis | VI:MRK |
| 2024-12-16 | — | 0.7228 EUR | 0.8/2.9 % | kord kvartalis | VI:MRK |
| 2024-09-16 | — | 0.6871 EUR | 0.7/2.6 % | kord kvartalis | VI:MRK |
| 2024-06-17 | — | 0.6871 EUR | 0.6/2.3 % | kord kvartalis | VI:MRK |
| 2024-03-14 | — | 0.6871 EUR | 0.6/2.4 % | kord kvartalis | VI:MRK |
| 2023-12-14 | — | 0.6871 EUR | 0.7/2.7 % | kord kvartalis | VI:MRK |
| 2023-09-14 | — | 0.6515 EUR | 0.6/2.6 % | kord kvartalis | VI:MRK |
| 2023-06-14 | — | 0.6515 EUR | 0.6/2.5 % | kord kvartalis | VI:MRK |
| 2023-03-14 | — | 0.6515 EUR | 0.7/2.6 % | kord kvartalis | VI:MRK |
| 2022-12-14 | — | 0.6515 EUR | 0.6/2.4 % | kord kvartalis | VI:MRK |
| 2022-09-14 | — | 0.6158 EUR | 0.7/2.8 % | kord kvartalis | VI:MRK |
| 2022-06-14 | — | 0.6158 EUR | 0.8/2.3 % | kord kvartalis | VI:MRK |
| 2022-03-14 | — | 0.6158 EUR | 0.8/1.7 % | kord kvartalis | VI:MRK |
| 2021-12-14 | — | 0.6158 EUR | 0.9/0.9 % | kord kvartalis | VI:MRK |
Suurimad Omanikud
| Omanik | Osalus | Aktsiad | Aruande Kuupäev |
|---|---|---|---|
| BlackRock | 9.2% | 227 mln | 2026-06-30 |
| Vanguard Capital Managem… | 6.54% | 161.32 mln | 2026-06-30 |
| State Street Corporation | 4.88% | 120.41 mln | 2026-06-30 |
| Wellington Management Gr… | 3.5% | 86.25 mln | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.18% | 78.41 mln | 2026-06-30 |
| Vanguard Portfolio Manag… | 2.75% | 67.74 mln | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.59% | 64 mln | 2026-06-30 |
| Geode Capital Management… | 2.46% | 60.74 mln | 2026-06-30 |
| Charles Schwab Investmen… | 2.2% | 54.37 mln | 2026-06-30 |
| Morgan Stanley | 1.97% | 48.64 mln | 2026-06-30 |
| FMR, LLC | 1.84% | 45.44 mln | 2026-06-30 |
| JPMORGAN CHASE & CO | 1.78% | 43.89 mln | 2026-06-30 |
| iShares Trust-iShares Co… | 1.33% | 32.89 mln | 2026-08-31 |
| Fidelity Concord Street… | 1.29% | 31.94 mln | 2026-07-31 |
| SCHWAB STRATEGIC TRUST-S… | 1.25% | 30.86 mln | 2026-05-31 |
| SPDR S&P 500 ETF TRUST-S… | 1.22% | 30.22 mln | 2026-08-31 |
| VANGUARD INDEX FUNDS-Van… | 0.95% | 23.51 mln | 2026-06-30 |
| SELECT SECTOR SPDR TRT-S… | 0.72% | 17.75 mln | 2026-08-31 |
| VANGUARD SPECIALIZED FUN… | 0.65% | 15.95 mln | 2026-07-31 |
| VANGUARD SPECIALIZED FUN… | 0.57% | 13.97 mln | 2026-07-31 |
| DAVIS ROBERT M (Chief Ex… | ≈0.02% | 450 351 | 2026-04-29 |
| CHATTOPADHYAY SANAT (Off… | ≈0.01% | 200 675 | 2026-04-29 |
| DELUCA RICHARD ROBERT JR… | ≈0% | 110 167 | 2026-08-12 |
| LI DEAN Y (Officer) | ≈0% | 94 431 | 2026-04-29 |
| LITCHFIELD CAROLINE (Chi… | ≈0% | 92 300 | 2026-04-29 |
| ZACHARY JENNIFER L (Gene… | ≈0% | 45 509 | 2026-08-12 |
| GUINDO CHIRFI (Officer) | ≈0% | 36 613 | 2026-08-13 |
| WILLIAMS DAVID MICHAEL (… | ≈0% | 31 716 | 2026-08-05 |
| ROMANELLI JOSEPH EDWARD… | ≈0% | 28 739 | 2026-01-26 |
| OOSTHUIZEN JOHANNES JACO… | ≈0% | 21 895 | 2026-04-29 |
| Trust for Professional M… | 0% | 24 803 | 2026-05-31 |
| Rhumbline Advisers | 0% | 10 919 | 2026-06-30 |
| SP Funds Trust-SP Funds… | 0% | 6 542 | 2026-07-31 |
| Atlas Capital Advisors I… | 0% | 2 467 | 2026-06-30 |
| Gamma Investing LLC | 0% | 2 302 | 2026-06-30 |
| Salomon & Ludwin, LLC | 0% | 356 | 2026-06-30 |
| PNC Financial Services G… | 0% | 2 | 2026-06-30 |
| The Vanguard Group | — | — | — |
Logi Sisse Google